Elanco Acquires Bayer’s Animal Health Business
Davis Polk is advising Duff & Phelps as financial adviser to the Board of Directors of Elanco Animal Health Incorporated in connection with its approximately $7.6 billion acquisition of…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Davis Polk Advises the Goldman Sachs Merchant Banking Division on Its Investment in MedVet
Davis Polk is advising the Goldman Sachs Merchant Banking Division in connection with its investment in MedVet.
Founded in 1869, The Goldman Sachs Group, Inc. is a leading global investment…
Davis Polk Advises Roche on Its Acquisition of Spark Therapeutics
Davis Polk is advising Roche on its approximately $4.3 billion acquisition of Spark Therapeutics, Inc. The transaction, which is expected to be completed in the second quarter of 2019, has…
Pernix Enters into an Agreement for the Sale of Substantially All of Its Assets Subject to a Competitive Bidding Process and Files for Chapter 11
Davis Polk is advising Pernix Therapeutics Holdings, Inc. in connection with its restructuring under chapter 11 of the United States Bankruptcy Code, entry into a “stalking horse” asset…
Bristol-Myers Squibb Acquires Celgene
Davis Polk is advising Morgan Stanley & Co. LLC, Evercore and Dyal Co. LLC as financial advisers to Bristol-Myers Squibb Company in connection with its approximately $74 billion…
Davis Polk Advises Nutrisystem on Its Acquisition by Tivity Health
Davis Polk is advising Nutrisystem, Inc. on its $1.4 billion acquisition by Tivity Health, Inc. The transaction, which is expected to close in the first quarter of 2019, is subject to…
Davis Polk Advises Mereo BioPharma Group plc on Its Combination with OncoMed Pharmaceuticals, Inc.
Davis Polk is advising Mereo BioPharma Group plc on its combination with OncoMed Pharmaceuticals, Inc. The transaction, which is subject to customary closing conditions and the approval of…
Davis Polk Advises Novo Nordisk on Its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma
Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…
Aetna receives DOJ approval of $77 billion acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…
Davis Polk Advises Aetna on the U.S. Department of Justice Approval of Its Acquisition by CVS Health
Davis Polk is advising Aetna in connection with an agreement with the U.S. Department of Justice that allows it to proceed with its proposed $77 billion acquisition by CVS Health and its…